Lilly/Seragen
Executive Summary
Firms reach final agreement Aug. 3 for Lilly to license Seragen's IL-2 fusion toxin for use in cancer therapies. Lilly agrees to fund all further development at an estimated cost of $17 mil. Payments to Seragen under the agreement, first announced in July ("The Pink Sheet" July 18, T&G-5), will total an additional $45 mil. Seragen also will pursue development of the fusion toxin for psoriasis